Clinical Evaluation of Microneedling Technique With Topical Application of Silymarin on Gingival Hyperpigmentation in Comparison With Diode Laser and Scalpel Methods.

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorFayoum University

About this trial

The present study will be carried to evaluate the efficacy of MN technique with topical Silymarin application in treating gingival hyperpigmentation in comparison with Laser and scalpel methods. This evaluation will be done clinically. The questions to be answered:

* Is there a statistical difference between the microneedling (MN) technique with topical silymarin application, the scalpel technique, and the diode laser in providing clinical and aesthetic advantages in the treatment of gingival pigmentation? * What medical problems do participants have when using of Silymarin topically?

Participants will be:

Group 1 : The gingiva of the facial surfaces of the selected area will be de-epithelized by conventional method through blades no 15c.

Group 2 : The gingiva of the facial surfaces of the selected area will be de-epithelized by A Diode laser Device (serolaser).

Group 3 : The gingiva of the facial surfaces of the selected area will be treated by repetitive punctures with Dr.Pen ULTIMA - A6 needle tip. Silymarin is applied topically for ten minutes.

Eligibility criteria

Qualifiers

Patients will be free from any systemic diseases according to criteria of Modified Cornell Medical Index

Patient with physiologic pigmentation

Non smoker

Patient agree to sign the written consent

Disqualifiers

Pregnant and lactating women

Systemic conditions affect melanin production

Medications induce pigmentation or enlargement

Those with known allergies to silymarin.

Trial design

Treatments tested in this trial

  • Gingival Depigmentation with Conventional Method
  • Gingival Depigmentation with Diode Laser
  • Gingival Depigmentation with Microneedling and Silymarin Application

Treatment groups

30 Participants
are divided into 3 treatment groups

Sponsors and collaborators